These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 19509481)

  • 21. Are nonnucleoside analogue-based regimens better than protease inhibitor-based regimens for nonadherent HIV-infected patients?
    Knobel H
    Clin Infect Dis; 2005 Jan; 40(1):164-6. PubMed ID: 15614707
    [No Abstract]   [Full Text] [Related]  

  • 22. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 drug resistance assays in clinical management.
    Martinez-Picado J; D'Aquila R
    AIDS Clin Care; 1998 Nov; 10(11):81-5, 87-8. PubMed ID: 11365861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of combined zidovudine and didanosine therapy in early asymptomatic primary HIV-1 infection.
    Khajotia RR; Feigley CE; Lee E; Gu J
    AIDS; 1998 Jan; 12(2):222-4. PubMed ID: 9468376
    [No Abstract]   [Full Text] [Related]  

  • 25. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
    Gupta SB; Pujari SN; Joshi SR; Patel AK;
    J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained immunological responses to highly active antiretroviral therapy at 36 months in a Ghanaian HIV cohort.
    Collini P; Schwab U; Sarfo S; Obeng-Baah J; Norman B; Chadwick D; Bibby D; Bedu-Addo G
    Clin Infect Dis; 2009 Apr; 48(7):988-91. PubMed ID: 19231976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial.
    Soria A; Danise A; Galli L; Tiberi S; Seminari E; Cossarini F; Bigoloni A; Marcotullio S; Lazzarin A; Castagna A
    J Clin Virol; 2010 Mar; 47(3):253-7. PubMed ID: 20056480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of total lymphocyte count for monitoring response to antiretroviral therapy.
    Schreibman T; Friedland G
    Clin Infect Dis; 2004 Jan; 38(2):257-62. PubMed ID: 14699459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salvage therapy.
    Gazzard B
    J HIV Ther; 2005 Mar; 10(1):3-5. PubMed ID: 15951727
    [No Abstract]   [Full Text] [Related]  

  • 30. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
    Reekie J; Mocroft A; Sambatakou H; Machala L; Chiesi A; van Lunzen J; Clumeck N; Kirk O; Gazzard B; Lundgren JD;
    AIDS; 2008 Nov; 22(17):2381-90. PubMed ID: 18981778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [HIV/AIDS: monitoring, the key to antiretroviral treatment efficacity].
    Rev Infirm; 2003 Feb; (88):8. PubMed ID: 12696347
    [No Abstract]   [Full Text] [Related]  

  • 34. [Monitoring anti-retroviral treatment].
    Miró JM; Pumarola T; Soriano V; Bouza E
    Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():44-50. PubMed ID: 9053027
    [No Abstract]   [Full Text] [Related]  

  • 35. Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype.
    Izopet J; Souyris C; Sandres-Sauné K; Puissant B; Obadia M; Pasquier C; Puel J; Blancher A; Massip P
    J Med Virol; 2002 Nov; 68(3):305-10. PubMed ID: 12226815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antiretroviral therapy in patients infected with HIV-1].
    Corti ME
    Medicina (B Aires); 1998; 58 Suppl 1():49-56. PubMed ID: 9674248
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of previous and present World Health Organization clinical staging criteria in HIV-infected Malawian children.
    Poerksen G; Nyirenda M; Pollock L; Blencowe H; Tembo P; Chesshyre E; Jefferis O; Kenny J; Moons P; Bunn J; Molyneux E
    AIDS; 2009 Sep; 23(14):1913-6. PubMed ID: 19584702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
    Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
    J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy and tolerance of antiretroviral therapy in HIV-2 infected patients in Dakar: preliminary study].
    Ndour CT; Batista G; Manga NM; Guèye NF; Badiane NM; Fortez L; Sow PS
    Med Mal Infect; 2006 Feb; 36(2):111-4. PubMed ID: 16480843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV drug resistance and nursing practice.
    Funesti Esch J; Frank SV
    Am J Nurs; 2001 Jun; 101(6):30-5; quiz 36. PubMed ID: 11441759
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.